<i>TP53</i> Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals by Kodal, Jakob B et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
TP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals
Kodal, Jakob B; Vedel-Krogh, Signe; Kobylecki, Camilla J; Nordestgaard, Børge G; Bojesen,
Stig E
Published in:
Scientific Reports
DOI:
10.1038/s41598-017-00427-x
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Kodal, J. B., Vedel-Krogh, S., Kobylecki, C. J., Nordestgaard, B. G., & Bojesen, S. E. (2017). TP53 Arg72Pro,
mortality after cancer, and all-cause mortality in 105,200 individuals. Scientific Reports, 7, [336].
https://doi.org/10.1038/s41598-017-00427-x
Download date: 03. Feb. 2020
1Scientific RepoRts | 7: 336  | DOI:10.1038/s41598-017-00427-x
www.nature.com/scientificreports
TP53 Arg72Pro, mortality after 
cancer, and all-cause mortality in 
105,200 individuals
Jakob B. Kodal1,2, Signe Vedel-Krogh1,2, Camilla J. Kobylecki1,2, Børge G. Nordestgaard1,2,3 & 
Stig E. Bojesen1,2,3
Rs1042522 (Arg72Pro) is a functional polymorphism of TP53. Pro72 has been associated with lower 
all-cause mortality and lower mortality after cancer. We hypothesized that TP53 Pro72 is associated 
with lower mortality after cancer, lower all-cause mortality, and with increased cancer incidence in the 
general population in a contemporary cohort. We genotyped 105,200 individuals aged 20–100 years 
from the Copenhagen General Population Study, recruited in 2003–2013, and followed them in Danish 
health registries. During follow-up 5,531 individuals died and 5,849 developed cancer. Hazard ratios for 
mortality after cancer were 1.03 (95% confidence interval:0.93–1.15) for Arg/Pro and 0.96 (95% CI:0.79–
1.18) for Pro/Pro versus Arg/Arg. Hazard ratios for all-cause mortality were 0.99 (95% CI:0.93–1.04) 
for Arg/Pro and 1.09 (95% CI:0.98–1.21) for Pro/Pro versus Arg/Arg. Risk of cancer specific mortality, 
cardiovascular mortality, and respiratory mortality were not associated with Arg72Pro genotype 
overall; however, in exploratory subgroup analyses, genotype-associated risks of malignant melanoma 
and diabetes were altered. Considering multiple comparisons the latter findings may represent play 
of chance. The TP53 Arg72Pro genotype was not associated with mortality after cancer, all-cause 
mortality, or cancer incidence in the general population in a contemporary cohort. Our main conclusion 
is therefore a lack of reproducing an effect of TP53 Arg72Pro genotype on mortality.
The tumor suppressor protein p53 regulates the response to oncogene activation and cellular stress. It functions 
as a transcription factor, hereby regulating apoptotic genes such as BAX and PERP as well as cell cycle arrest genes 
such as CDKN1A. Also, through interaction with other proteins, such as members of the BCL-2 family, p53 can 
initiate mitochondrial apoptotic events1. Somatic mutations in the TP53 gene, encoding the p53 protein, are pres-
ent in approximately half of all human cancers2, and it is the most frequently mutated gene in cancers3. In mice, 
enhanced p53 activity is associated with a higher resistance to spontaneous tumor development, but also with 
shorter lifespan and an earlier onset of some, but not all phenotypes associated with aging4, 5.
The germline single nucleotide polymorphism rs1042522 (Arg72Pro) is an arginine (Arg) to proline (Pro) 
substitution in codon 72, and the two p53 variants differ in how they influence downstream cellular processes; 
the Arg72 variant induces apoptosis five times better than the Pro72 variant, likely through a greater ability of 
the Arg72 variant to localize to the mitochondria6 and to increase transcription of a number of pro-apoptotic 
p53-regulated genes7.
The Arg72Pro polymorphism has been extensively studied as a risk factor for development of cancer in can-
didate gene studies8–13; however, candidate gene studies can be of low quality and may suffer from a variety of 
reporting, analysis, and genotyping biases14–16. Fewer studies have examined the association of the Arg72Pro 
polymorphism with all-cause mortality. At present, only two cohort studies recruiting individuals in 1987–199917 
and 1991–199418 have addressed this question and both found a lower mortality among homozygotes for the 
Pro72 variant17, 18. Collectively, results from these studies support that the Arg72Pro influences all-cause mortality 
and mortality after cancer. We hypothesized that TP53 Pro72 is associated with lower mortality after cancer, lower 
all-cause mortality, and with increased cancer incidence in the general population in a contemporary cohort.
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Methods
Study population. We included 105,200 individuals aged 20–100 years from the Copenhagen General 
Population Study, a prospective population-based cohort study initiated in 2003 with ongoing enrolment. All 
Danes are given a unique number for identification at birth or immigration and are registered in the national 
Danish Civil Registration System. This unique identification number can then be used to follow the participants 
through the national registers with complete follow-up19. Danish inhabitants of suburban Copenhagen areas 
were invited using the national Danish Civil Registration System. In order to minimize the risk of population 
stratification, only individuals of Danish descent were included. All participants filled out an extensive question-
naire on life-styles and health, which was reviewed by the participant together with an investigator at the day of 
study attendance, had a physical examination done, and had blood samples taken for biochemical analysis and 
DNA extraction. The study was approved by Herlev and Gentofte Hospital, a Danish ethics committee, and was 
conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants.
Endpoints. We followed all individuals until death (n = 5,531), emigration (n = 392) or November 14, 2014, 
whichever came first. No individuals were lost to follow-up. Date of death or emigration was obtained from the 
national Danish Civil Registration System. Causes of death were obtained from the national Danish Causes of 
Death Registry. Records rank main and contributing causes of death as reported by general practitioner, hospital 
doctor, or by a physician in a forensic or pathology department, using WHO’s tenth International Classification 
of Diseases (ICD-10)20. Cause of death was defined as cancer specific, cardiovascular, or respiratory if the highest 
ranked cause of death was a diagnosis of cancer (ICD-10 C00-C97), cardiovascular disease (ICD-10 I00-I99), or 
respiratory disease (ICD-10 J00-J99), respectively. If the highest ranked cause of death was none of the above, but 
a diagnosis was available, then cause of death was categorized as “other”. Information on the diagnosis of cancer 
until December 31, 2012 was obtained from the national Danish Cancer Registry, which was established in 1943. 
Since 1987, it has been compulsory for all physicians by law to report cancer diagnosis to the national Danish 
Cancer Registry21. Cancer diagnoses were assembled into 8 groups to maximize statistical power. Gastrointestinal 
cancer included pharynx, esophagus, stomach, colon, rectum, liver, and pancreas cancer. Respiratory cancer 
included larynx and lung cancer. Urologic cancer included bladder and kidney cancer. Hematologic cancer 
included non-Hodgkin lymphoma, Hodgkin disease, multiple myeloma, and leukaemia. Male cancer included 
prostate and testis cancer. Female cancer included female breast, cervix uteri, corpus uteri, and ovary cancer. 
Other cancers included brain and central nervous system, thyroid cancer, sarcomas, and cancer of unknown 
primary origin.
Genotypes. We extracted DNA from leukocytes in peripheral blood using Qiagen blood kit for DNA 
extraction. Genotyping of 105,200 individuals for the TP53 rs1042522 (Arg72Pro) variant was done with a 
TaqMan-based assay (Applied Biosystems). Sequence of primers and probes are available upon request. Samples 
with failed genotyping were attempted to be genotyped again, and a second time if failed. Thereby, 99.9% of avail-
able samples were genotyped. Control samples for correct genotyping were obtained from the Copenhagen City 
Heart Study, previously genotyped using a different technique18, 22.
Covariates. Information on covariates was derived from the questionnaire, physical examination, and blood 
measurements recorded at the day of attendance. We defined physical inactivity as being completely physically 
inactive or physical active for a maximum of two hours per week. Completed higher education was defined as 
having a higher education of 3 years or longer. High annual household income was defined as more than 600,000 
DKK per year, equivalent to 80,625 euros. Weekly alcohol intake was self-reported number of units, converted 
to g/week (1 unit ≈12 g). Cumulative smoking in pack-years was calculated as the cumulated amount of tobacco 
smoked by the individual, divided by the equivalent of smoking 20 cigarettes a day for an entire year. Diabetes was 
defined as self-reported diabetes, use of insulin, use of oral antidiabetics, nonfasting blood glucose >11 mmol/L 
(198 mg/dL) at the day of examination, and/or a diagnosis of diabetes in the national Danish Patient Registry 
before the date of baseline examination. Body mass index was calculated as measured weight in kilograms divided 
by measured height in meters squared. Plasma cholesterol was measured using a standard hospital assay.
Statistical analysis. We used Stata/SE 13.1. We used Cuzick’s nonparametric test for trend to test for asso-
ciations of genotype with baseline characteristics. The Hardy-Weinberg Equilibrium hypothesis was tested using 
Pearson’s χ2 test.
Hazard ratios for mortality after cancer were calculated using Cox proportional hazards regression analysis 
adjusted for sex and age (as underlying time scale), since Arg72Pro was not associated with any of the measured 
potential confounders included in baseline characteristics in Table 1. We included all individuals who received 
a cancer diagnosis after the examination date and before December 31, 2012, the date where cancer follow-up 
ended. In these analyses, entry was defined as the day of cancer diagnosis.
For all-cause mortality, all individuals were included. Hazard ratios were calculated using Cox proportional 
hazards regression analysis adjusted for sex and age (as time scale), with entry as the day of examination. For risk 
of cancer, we used Cox proportional hazards regression analysis adjusted for sex and age (as time scale), with 
entry at birth or at the start of the Danish cancer registry if individuals were born before January 1, 1943.
Proportional hazards over time were assessed based on Schoenfeld residuals. No major violations of the pro-
portional hazard assumption were noted.
Interactions between Arg72Pro genotype and age, sex, smoking status, and body mass index, covariates that 
could influence the association between genotype and all-cause mortality, were tested using the Likelihood-ratio 
test by introducing a two-factor interaction term in a model including both factors. Estimates with confidence 
intervals from other studies were compared with our results using the Bland-Altman test23. A meta-analysis 
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was conducted using the method of DerSimonian and Laird, with the estimate of heterogeneity taken from the 
Mantel-Haenszel model. This method takes the number of individuals per study into consideration.
P-values were calculated from two-tailed analyses and nominal values are shown throughout the paper. For 
each display item, several exploratory analyses were performed, lowering the p-value required for significance 
below the conventional 0.05. Therefore, we note the significance cut-off a.m. Bonferroni in all the figure and table 
legends.
Results
Among the 105,200 individuals from the Copenhagen General Population Study, rs1042522 (Arg72Pro) genotype 
frequencies were 54% for Arg/Arg homozygotes, 39% for Arg/Pro heterozygotes, and 7% for Pro/Pro homozy-
gotes, not differing from Hardy-Weinberg equilibrium (p-value = 0.39). Baseline characteristics did not differ 
across Arg72Pro genotypes (Table 1), nor after stratification according to sex (Table 2). Median follow-up was 5.6 
years (interquartile range: 3.0–8.1 years).
Mortality after cancer. 5,849 individuals developed cancer after the baseline examination, and 1,529 of 
these died during follow-up. The hazard ratio for mortality after cancer was 1.03 (95% confidence interval (CI): 
0.93–1.15) for individuals with Arg/Pro and 0.96 (95% CI: 0.79–1.18) for Pro/Pro versus individuals with Arg/Arg 
(Fig. 1). When restricting follow-up to 5 years after the diagnosis of cancer, results were similar (Fig. 1).
All-cause mortality. During follow-up, 5,531 of the 105,200 individuals died. The hazard ratio for all-cause 
mortality was 0.99 (95% CI: 0.93–1.04) for individuals with Arg/Pro and 1.09 (95% CI: 0.98–1.21) for Pro/Pro 
versus individuals with Arg/Arg (Fig. 1). Results were similar when restricting analyses to those of 85 years and 
older (data not shown), as done in a previous study17. We found no interaction of the Arg72Pro genotype with 
age, sex, smoking status, or body mass index on mortality risk (data not shown). In a meta-analysis of the results 
from this and the published studies on Arg72Pro and all-cause mortality, the estimates were heterogeneous for 
both the Pro/Pro versus Arg/Arg (I2 = 84%, p = 0.002), and for the Arg/Pro versus Arg/Arg (I2 = 79%, p = 0.03) 
analyses. Overall, there was no association between Arg72Pro genotype and all-cause mortality (Fig. 2). When 
assessing cause-specific mortality, we found no association of the Arg72Pro genotype with cancer specific mor-
tality, cardiovascular specific mortality, or respiratory specific mortality (Fig. 3).
The Arg72Pro and cancer incidence. For malignant melanoma, the hazard ratio was 0.87 (95% CI: 0.77–
0.99) for individuals with Arg/Pro and 0.78 (95% CI: 0.60–1.01) for Pro/Pro versus individuals with Arg/Arg with 
a nominally significant trend for a per-allele effect (p = 0.01); however, this was not significant after Bonferroni 
correction for eight tests. No other associations between Arg72Pro and cancer incidence were found (Fig. 4), 
nor between Arg72Pro and incidence of sex-specific cancers (Table 2). Likewise, when stratifying on cancer sub-
types there was no association between Arg72Pro and cancer incidence after correcting for multiple comparisons 
(Supplementary Figure S1).
Discussion
In this study of 105,200 individuals from the general population recruited in 2003–2013, we found no differ-
ence in risk of mortality after cancer, all-cause mortality, or cancer incidence according to Arg72Pro genotype. 
Characteristic
Arg72Pro genotype
Arg/Arg Arg/Pro Pro/Pro p-value
Individuals 56,559 (54) 41,233 (39) 7,408 (7)
Male 25,464 (45) 18,475 (45) 3,376 (46) 0.86
Age, years 58 (48–67) 58 (48–67) 58 (48–67) 0.78
Physically inactive 3,506 (6) 2,508 (6) 480 (6) 0.87
Completed higher education 25,688 (45) 18,749 (45) 3,383 (46) 0.71
High annual household income 24,387 (43) 17,814 (43) 3,265 (44) 0.23
Alcohol, g/wk 96 (48–180) 96 (48–180) 96 (48–180) 0.10
Current or former smoker 33,031 (58) 24,085 (58) 4,253 (57) 0.29
Total tobacco consumption, 
pack-yearsc 15 (6–30) 15 (6–30) 15 (6–30) 0.51
Diabetes mellitus 2,692 (5) 2,058 (5) 377 (5) 0.07
Body mass index, kg/m2 25.6 (23.2–28.5) 25.5 (23.2–28.4) 25.5 (23.2–28.4) 0.04NS
Systolic blood pressure, mmHg 140 (126–155) 140 (126–155) 140 (126–155) 0.94
Plasma cholesterol, mmol/liter 5.5 (4.8–6.3) 5.5 (4.9–6.3) 5.5 (4.9–6.3) 0.11
Table 1. Baseline characteristics according to TP53 Arg72Pro genotype in individuals in the general 
population. Data are expressed as number and percentage for categorical values and median and interquartile 
range for continuous values. Total tobacco consumption was calculated for current and former smokers only. 
P-values were calculated using Cuzick’s test for trend, and the nominal p-values are shown without prior 
adjustment for multiple comparisons. NSInsignificant after Bonferroni correction for 12 multiple tests. Required 
p-value = 0.004 (=0.05/12).
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In exploratory subgroup analyses, genotype associated risks of malignant melanoma and diabetes were altered. 
Considering multiple comparisons, these findings may represent play of chance.
The association between malignant melanoma and Arg72Pro genotype has been studied by several groups due 
to a geographical latitude gradient in allele distribution. Among South Africans, 70% of the alleles are Pro72 com-
pared to only 23% among Western Europeans24. This has led to the hypothesis that the Pro72 allele is protective 
against sunlight induced diseases25. However, meta-analyses of both non-melanoma skin cancer and malignant 
melanoma have found no association between Arg72Pro and risk of these cancers26.
The Arg72Pro polymorphism has been extensively studied as a risk factor for development of cancer. Several 
meta-analyses have been conducted in various cancers including cervical, breast, skin, head, and neck cancer8–13. 
However, the results have been inconsistent with reports of potential publication bias9, 11 and of genotype mis-
classification in association studies using tumor tissue as a source of genotyping material15. No genome-wide 
association study has found an association between Arg72Pro and risk of a cancer27.
In a recent meta-analysis, the Arg72 allele of Arg72Pro was associated with increased odds of type 2 diabetes28, 29. 
Although, we did find an association between diabetes and genotype at baseline examination in women only, 
this association did not remain after correction for multiple comparisons, suggesting that the association may 
represent play of chance.
Endpoint N Events
Arg/Arg Arg/Pro Pro/Pro
p for 
trendHR HR (95% CI)
HR (95% 
CI)
Male
 Prostate cancer 39,502 1,652 1.00 0.95 (0.86–1.05)
0.90 
(0.74–1.10) 0.21
 Testicular cancer 39,502 245 1.00 1.23 (0.95–1.60)
0.87 
(0.50–1.51) 0.50
Baseline characteristics, n (%) or median (IQR)
 Age, years 47,315 59 (49–68) 58 (48–68) 58 (48–68) 0.12
 Alcohol, g/wk 47,315 144 (72–240) 144 (72–240) 144 (72–240) 0.06
 Current or former 
smoker 47,315 15,847 (62) 11,456 (62) 2,078 (62) 0.42
 Total tobacco 
consumption, pack-
years
29,381 20 (9.0–36) 20 (9.0–35) 20 (9.0–35) 0.53
 Diabetes mellitus 47,315 1,523 (6) 1,125 (6.1) 193 (5.7) 0.91
 Body mass index, kg/m2 47,315 26 (24–29) 26 (24–29) 26 (24–29) 0.07
Female
 Breast cancer 48,473 2,793 1.00 1.01 (0.93–1.09)
1.11 
(0.96–1.28) 0.34
 Cervix cancer 48,473 287 1.00 0.84 (0.66–1.08)
0.93 
(0.59–1.48) 0.29
 Uterus cancer 48,473 455 1.00 1.01 (0.83–1.23)
0.97 
(0.67–1.41) 0.99
 Ovary cancer 48,473 264 1.00 0.97 (0.75–1.24)
0.79 
(0.46–1.34) 0.45
Baseline characteristics, n (%) or median (IQR)
 Age, years 57,885 57 (48–67) 58 (48–67) 58 (48–67) 0.08
 Alcohol, g/wk 57,885 72 (36–132) 72 (36–132) 72 (36–132) 0.67
 Current or former 
smoker 57,885 17,184 (55) 12,629 (55) 2,175 (54) 0.47
 Total tobacco 
consumption, pack-
years
31,988 12 (4.5–24) 12 (4.5–25) 12 (4.5–25) 0.69
 Diabetes mellitus 57,885 1,169 (3.8) 933 (4.1) 184 (4.6) 0.004NS
 Body mass index, kg/m2 57,885 25 (22–28) 25 (22–28) 25 (22–28) 0.22
Table 2. Incidence of sex-specific cancers and distribution of baseline characteristics according to sex and TP53 
Arg72Pro genotype. Data on baseline characteristics are expressed as number and percentage for categorical 
values and median and interquartile range (IQR) for continuous values. Hazard ratios for cancer endpoints were 
adjusted for sex and age. Follow-up started at the day of birth or for individuals born before 1943 at the start of 
the national Danish Cancer Registry and ended at cancer diagnosis, death, emigration, or December 31, 2012 
whichever came first. Total tobacco consumption was calculated for current and former smokers only. P-values 
were calculated using Cuzick’s test for trend or a Cox regression using Arg72Pro genotype as a continuous 
variable. The nominal values are shown without prior adjustment for multiple comparisons. NSInsignificant 
after Bonferroni correction for 18 multiple tests. Required p-value = 0.003 (=0.05/18). HR, Hazard ratio; CI, 
Confidence interval.
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Two human cohort studies have evaluated the association between all-cause mortality and the Arg72Pro gen-
otype. A Dutch study of individuals aged 85 years or older, the Leiden 85-plus Study including 1,226 individuals, 
reported a higher survival ratio for Pro/Pro versus Arg/Arg homozygotes but also a higher proportion of death 
from cancer among Pro/Pro homozygotes17. Similarly, a Danish study of 9,219 individuals aged 20–100 years 
from the Copenhagen City Heart Study reported lower mortality for both Pro/Pro and Pro/Arg versus Arg/
Arg18. This study also found increased survival after a diagnosis of any cancer for Pro/Pro versus Arg/Arg. These 
Figure 1. Hazard ratios for mortality after cancer and for all-cause mortality according to TP53 Arg72Pro 
genotype in the general population. Hazard ratios were adjusted for sex and age in all analyses. Follow-up 
started at first cancer diagnosis after baseline (mortality after cancer) or the day of baseline examination (all-
cause mortality), and ended on the day of death, emigration or November 14, 2014, whichever came first. 
In the mortality after cancer analysis with 5 year follow-up, follow-up ended 5 year after cancer diagnosis, 
death, emigration, or November 14, 2014 whichever came first. In the all-cause mortality analysis with 5 
year follow-up, follow-up ended 5 year after baseline examination, death, emigration, or November 14, 2013 
whichever came first. CI; Confidence interval. HR; Hazard ratio.
Figure 2. Meta-analysis of hazard ratios for all-cause mortality according to TP53 Arg72Pro genotype in 3 
longitudinal studies. Hazard ratios were adjusted for sex and age. The hazard ratio for Arg/Pro vs. Arg/Arg was 
not reported in the Leiden 85-plus Study. CCHS; Copenhagen City Heart Study. CGPS; Copenhagen General 
Population Study. CI; Confidence interval. HR; Hazard ratio. Leiden-85; The Leiden 85-plus Study.
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studies suggest a survival benefit for the Pro72 allele, possible through a lower apoptotic-inducing potential17, 18. 
However, our results do not support this.
Our result on all-cause mortality in individuals recruited in 2003–2014, was indeed different from those in 
the two previous studies recruited in 1987–1999 and 1991–1994 (Figs 2 and 5). The lack of association between 
Arg72Pro and all-cause mortality observed in the present study could indicate a gene-environment interaction 
with a change in effect of Pro72 on mortality over calendar time. The disappearing association with reduced 
all-cause mortality could be caused by more effective prevention or treatments of factors limiting the longevity 
of Arg72 homozygotes. Additionally, secular trends in mortality as well as in lifestyle and environmental changes 
could interact with the Arg72Pro genotype and eliminate a survival effect of the Pro72 allele; possible mecha-
nisms may be examined in future studies. Changes in cancer treatment and cancer survival in Denmark during 
the past twenty years could have led to a diminished effect of Arg72Pro on mortality after cancer30, 31. In support 
of this, a German study with 463 cases and 563 controls, found a possible gene-environment interaction between 
Arg72Pro and the preventive effect of nonsteroidal anti-inflammatory drugs (NSAID) on risk of colon cancer; 
Pro72 carriers had a low risk regardless of NSAID use, while Arg72 homozygotes had low risk only when taking 
NSAID32. Recent trends in use of NSAID and aspirin show increasing usage of ibuprofen and low dosage aspi-
rin33. This could be one example of an interaction between Arg72Pro genotype and environment, an interaction 
that may have changed over time and that could influence mortality.
Although the concept of a secular trend between the Arg72Pro polymorphism and all-cause mortality is 
intriguing, a simpler theoretical explanation may be that many of the studies on TP53 Arg72Pro and cancer 
Figure 3. Cause-specific mortality according to TP53 Arg72Pro genotype in individuals in the general 
population. Hazard ratios were adjusted for age and sex. Follow-up started at the day of baseline examination 
and ended at death, emigration or November 14, 2014 whichever came first. Death endpoints were collected 
from the Danish Civil Registration System. Cause of death was collected from the Danish Register of Causes 
of Death. The sum of all events is lower than the sum of all-cause mortality events in Fig. 1 since the Danish 
Register of Causes of Death lags slightly behind the registration of all-cause mortality. Also, the sum of events 
differs from the number of deaths among cancer diagnosed individuals which are shown in Fig. 1. p-values for 
trend were calculated using Cox regression with Arg72Pro genotype as a continuous variable. CI; Confidence 
interval. HR; Hazard ratio.
Figure 4. Risk of cancer according to TP53 Arg72Pro genotype in individuals in the general population. 
Hazard ratios were adjusted for sex and age. Follow-up started at the day of birth or for individuals born before 
1943 at the start of the national Danish Cancer Registry and ended at cancer diagnosis, death, emigration, or 
December 31, 2012 whichever came the first. p-values for trend were calculated with Cox regression using 
Arg72Pro genotype as a continuous variable, and the nominal values are shown without prior adjustment for 
multiple comparisons. NSInsignificant after Bonferroni correction for 8 multiple tests. Required p-value = 0.006 
CI; Confidence interval. HR; Hazard ratio.
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incidence did actually examine the associations with all-cause mortality, but did not publish a lack of association. 
This in turn could create selective reporting and hence publication bias of the association. Such a possibility 
together with the effect of genotype misclassification and genotyping errors in candidate gene studies14, 16 might 
explain the discrepancies between previous studies and our findings. As only two other studies have published on 
the association between the Arg72Pro polymorphism and all-cause mortality17, 18, we were not able to statistically 
evaluate the hypothesis of a publication bias. That said, a meta-analysis combining the results from the two earlier 
studies with ours showed no association between Arg72Pro genotype and all-cause mortality (Fig. 2). Finally, we 
cannot exclude the possibility that the earlier findings, or the present, came from play of chance.
This study is by far the largest cohort study examining the effect of Arg72Pro on all-cause mortality and 
mortality after cancer; however, some limitations should be considered. First, since our study population con-
sists solely of individuals of Danish descent our findings might not apply to other ethnicities; however, this also 
minimizes the risk of population stratification. Second, we were not able to evaluate gene-gene-interactions such 
as with the mouse double minute 2 (MDM2) promoter SNP 309 and hence cannot exclude the existence of an 
interaction. Also, although we include a large number of individuals, 11,316 cancer events, and 5,531 deaths, we 
cannot rule out an effect of the Arg72Pro too small for our study to detect. Additionally, the use of Bonferroni 
correction diminishes the likelihood of chance findings (type I errors) due to multiple testing, but also increases 
the risk of ignoring important association (type II errors). Hence some associations displayed in Table 1, Table 2, 
Fig. 4 and Supplementary Figure S1 that did not meet the required level of significance after Bonferroni correction 
but did meet conventional level of significance (p-value < 0.05), could represent true associations. Importantly, 
however these findings need validation in future studies.
In conclusion, the TP53 Arg72Pro genotype was not associated with lower mortality after cancer, lower 
all-cause mortality, or cancer incidence in the general population in a contemporary cohort. Our main conclusion 
is therefore a lack of reproducing an effect of TP53 Arg72Pro genotype on mortality.
Data availability. Individual participant data from the Copenhagen General population Study are subject to 
protection from the national Danish Data Protection Agency and we are not allowed to share the data. However, 
interested researchers can contact members of the Copenhagen General Population Study steering committee 
(http://binanic.com/CGPS/Contacts.htm) to request limited data access. Additional data are available upon 
request and requests may be made to the corresponding author.
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